MCID: HYP069
MIFTS: 58

Hyperparathyroidism malady

Categories: Endocrine diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Hyperparathyroidism

Aliases & Descriptions for Hyperparathyroidism:

Name: Hyperparathyroidism 12 29 52 42 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:13543
ICD10 33 E21.3
ICD9CM 35 252.0 252.00
MeSH 42 D006961
NCIt 47 C48259
UMLS 69 C0020502

Summaries for Hyperparathyroidism

Disease Ontology : 12 A parathyroid gland disease characterized by an overactivity of the parathyroid glands, leading to an excess of parathyroid hormone in the body.

MalaCards based summary : Hyperparathyroidism is related to hyperparathyroidism, familial primary and parathyroid carcinoma. An important gene associated with Hyperparathyroidism is CASR (Calcium Sensing Receptor), and among its related pathways/superpathways are Nuclear Receptors in Lipid Metabolism and Toxicity and Development_Hedgehog and PTH signaling pathways in bone and cartilage development. The drugs Benzocaine and Sevelamer have been mentioned in the context of this disorder. Affiliated tissues include bone, kidney and thyroid, and related phenotypes are Decreased viability and growth/size/body region

Wikipedia : 71 Hyperparathyroidism is an increased parathyroid hormone (PTH) levels in the blood. This occurs either... more...

Related Diseases for Hyperparathyroidism

Diseases in the Hyperparathyroidism family:

Hyperparathyroidism, Familial Primary Hyperparathyroidism 3

Diseases related to Hyperparathyroidism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 340)
id Related Disease Score Top Affiliating Genes
1 hyperparathyroidism, familial primary 33.9 CASR CDC73 MEN1 RET
2 parathyroid carcinoma 30.6 ACP5 BGLAP CALCA CASR CDC73 CHGA
3 parathyroid gland disease 30.5 CASR FGF23 PRKAR1A PTH PTHLH
4 pheochromocytoma 29.9 CALCA CHGA MEN1 RET
5 hyperparathyroidism-jaw tumor syndrome 12.5
6 hyperparathyroidism 3 12.3
7 hyperparathyroidism, neonatal 12.3
8 secondary hyperparathyroidism of renal origin 12.2
9 hypophosphatemic rickets and hyperparathyroidism 12.0
10 hyperparathyroidism, primary, caused by water clear cell hyperplasia 11.8
11 nephropathy, deafness, and hyperparathyroidism 11.8
12 non-renal secondary hyperparathyroidism 11.8
13 cdc73-related familial isolated hyperparathyroidism 11.7
14 osteitis fibrosa 11.6
15 parathyroid adenoma 11.3
16 nephrocalcinosis 11.2
17 multiple endocrine neoplasia 1 11.2
18 familial hypocalciuric hypercalcemia 11.1
19 rickets 11.1
20 multiple endocrine neoplasia iia 10.9
21 chondrocalcinosis 2 10.7
22 basilar impression, primary 10.7
23 osteopetrosis, autosomal recessive 1 10.7
24 hypophosphatemic rickets, autosomal dominant 10.7
25 rickets, vitamin d-resistant, type iia 10.7
26 vitamin d-dependent rickets, type i 10.7
27 adenoma 10.4
28 macular holes 10.3 MEN1 PTH
29 restless legs syndrome 7 10.3 CDC73 MEN1
30 hypochondrogenesis 10.3 BGLAP PTH
31 familial chronic myelocytic leukemia-like syndrome 10.3 CASR CDC73 PTH
32 multiple endocrine neoplasia 10.3
33 immune system organ benign neoplasm 10.3 CDC73 MEN1 PTH
34 jessner's lymphocytic infiltration of the skin 10.3 CASR PRKAR1A
35 epilepsy idiopathic generalized 8 10.3 CASR NR1I3 PRKAR1A
36 hypophosphatasia, adult 10.3 BGLAP CALCA PTH
37 prediabetes syndrome 10.3 BGLAP FGF23 PTH
38 hirschsprung disease 1 10.2 CALCA MEN1 RET
39 primary release disorder of platelets 10.2 BGLAP PTHLH
40 phka2-related phosphorylase kinase deficiency 10.2 CALCA TNFRSF11B
41 stickler syndrome 10.2 CALCA PTH TNFRSF11B
42 osseous heteroplasia, progressive 10.2 FGF23 MEN1 PRKAR1A
43 epilepsy, idiopathic generalized 14 10.2 BGLAP FGF23 TNFRSF11B
44 weill-marchesani syndrome 10.2 CASR FGF23 PTH VDR
45 mesenchymal cell neoplasm 10.2 BGLAP CALCA CASR PTH
46 toxicodendron dermatitis 10.2 BGLAP PTH PTHLH
47 bowen-conradi syndrome 10.2 CDKN1B MEN1 PRKAR1A
48 kidney disease 10.2
49 strabismus 10.2 MEN1 PTH PTHLH
50 thyroiditis 10.2

Comorbidity relations with Hyperparathyroidism via Phenotypic Disease Network (PDN):


Acute Cystitis Chronic Kidney Failure
Deficiency Anemia Hypertension, Essential
Hypoparathyroidism Hypothyroidism
Nephrolithiasis, Type I Osteoporosis
Parathyroid Carcinoma

Graphical network of the top 20 diseases related to Hyperparathyroidism:



Diseases related to Hyperparathyroidism

Symptoms & Phenotypes for Hyperparathyroidism

GenomeRNAi Phenotypes related to Hyperparathyroidism according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.5 CDKN1B NR1I3 PRKAR1A RET TNFRSF11B
2 Decreased viability GR00221-A-2 9.5 NR1I3 PRKAR1A RET TNFRSF11B
3 Decreased viability GR00221-A-3 9.5 PRKAR1A
4 Decreased viability GR00221-A-4 9.5 PRKAR1A RET
5 Decreased viability GR00231-A 9.5 RET
6 Decreased viability GR00301-A 9.5 NR1I3 RET

MGI Mouse Phenotypes related to Hyperparathyroidism:

44 (show all 18)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.39 CDC73 CDKN1B CHGA CYP27B1 FGF23 MEN1
2 cardiovascular system MP:0005385 10.38 CDKN1B CHGA CYP27B1 EPO FGF23 MEN1
3 homeostasis/metabolism MP:0005376 10.38 PHEX PRKAR1A PTH PTHLH RET VDR
4 cellular MP:0005384 10.37 CASR CDC73 CDKN1B CYP27B1 EPO MEN1
5 endocrine/exocrine gland MP:0005379 10.34 GAST MEN1 PRKAR1A PTH PTHLH RET
6 immune system MP:0005387 10.33 CASR CDC73 CDKN1B CYP27B1 EPO FGF23
7 hematopoietic system MP:0005397 10.31 CASR CDC73 CDKN1B CYP27B1 EPO FGF23
8 digestive/alimentary MP:0005381 10.28 CASR CDC73 CDKN1B FGF23 GAST MEN1
9 mortality/aging MP:0010768 10.27 VDR CASR CDC73 CDKN1B CHGA EPO
10 craniofacial MP:0005382 10.2 CDKN1B CYP27B1 MEN1 PHEX PRKAR1A PTH
11 limbs/digits/tail MP:0005371 10.06 CYP27B1 EPO FGF23 PHEX PTH PTHLH
12 adipose tissue MP:0005375 10.05 CDC73 CDKN1B CYP27B1 PHEX PRKAR1A PTHLH
13 integument MP:0010771 10.03 CASR CDC73 CDKN1B CYP27B1 EPO FGF23
14 renal/urinary system MP:0005367 9.96 CASR CDC73 CDKN1B CHGA CYP27B1 FGF23
15 muscle MP:0005369 9.92 CASR CDC73 CDKN1B EPO MEN1 PRKAR1A
16 reproductive system MP:0005389 9.9 CDC73 CDKN1B CHGA CYP27B1 FGF23 MEN1
17 respiratory system MP:0005388 9.5 RET CDC73 CDKN1B EPO FGF23 PRKAR1A
18 skeleton MP:0005390 9.36 CASR CDKN1B CYP27B1 EPO FGF23 PHEX

Drugs & Therapeutics for Hyperparathyroidism

Drugs for Hyperparathyroidism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 192)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
2
Sevelamer Approved Phase 4,Phase 3,Phase 2 52757-95-6, 152751-57-0 3085017
3
Denosumab Approved Phase 4,Phase 3,Phase 1 615258-40-7
4
Alendronate Approved Phase 4,Phase 2 121268-17-5, 66376-36-1 2088
5 Strontium ranelate Approved Phase 4 135459-87-9
6
Darbepoetin alfa Approved, Investigational Phase 4 11096-26-7, 209810-58-2
7
Calcium acetate Approved Phase 4 62-54-4
8
Calcium carbonate Approved Phase 4,Phase 3,Phase 2 471-34-1
9
Zoledronic acid Approved Phase 4,Phase 1 118072-93-8 68740
10
Pamidronate Approved Phase 4 40391-99-9 4674
11
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
12
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
13
Iron Approved Phase 4 7439-89-6 23925
14
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-14-6 5280793
15 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
16
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 67-97-0 6221 10883523 5280795
17
Calcitriol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 32222-06-3 134070 5280453
18
Alfacalcidol Approved, Nutraceutical Phase 4,Phase 2 41294-56-8 5282181
19
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 59-30-3 6037
21
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
22
Nicotinamide Approved, Nutraceutical Phase 4 98-92-0 936
23 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Calcimimetic Agents Phase 4,Phase 2,Phase 3,Phase 1
25 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Cinacalcet Hydrochloride Phase 4,Phase 2,Phase 3,Phase 1
27 Ergocalciferols Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
29 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
31 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 vitamin d Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Vitamins Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 1 alpha-hydroxyergocalciferol Phase 4,Phase 3,Phase 2,Phase 1
36 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Hydroxycholecalciferols Phase 4,Phase 3,Phase 2
38 Calcifediol Phase 4,Phase 3,Phase 1 19356-17-3
39 Antimetabolites Phase 4,Phase 2
40 Hypolipidemic Agents Phase 4,Phase 2
41 Lipid Regulating Agents Phase 4,Phase 2
42 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
43 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1
44 Epoetin alfa Phase 4 113427-24-0
45 Hematinics Phase 4
46 Anticholesteremic Agents Phase 4
47 Atorvastatin Calcium Phase 4 134523-03-8
48 Chelating Agents Phase 4,Phase 3,Phase 2
49 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
50 Liver Extracts Phase 4

Interventional clinical trials:

(show top 50) (show all 313)
id Name Status NCT ID Phase
1 Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients Unknown status NCT02338934 Phase 4
2 Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity Unknown status NCT00288873 Phase 4
3 How Bone is Made in Children Receiving Dialysis Unknown status NCT01799317 Phase 4
4 Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients Unknown status NCT01512862 Phase 4
5 Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism Completed NCT00307840 Phase 4
6 Denosumab in Primary Hyperparathyroidism Completed NCT01558115 Phase 4
7 A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer Completed NCT00037518 Phase 4
8 Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis Completed NCT01181531 Phase 4
9 Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Completed NCT00537979 Phase 4
10 Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism Completed NCT01143987 Phase 4
11 Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation Completed NCT01178450 Phase 4
12 Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism Completed NCT02417389 Phase 4
13 ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism Completed NCT00135304 Phase 4
14 Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate Completed NCT01222026 Phase 4
15 Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism Completed NCT01115543 Phase 4
16 Evaluation of a Cincalcet Suppression Test Completed NCT01103206 Phase 4
17 Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) Completed NCT00823303 Phase 4
18 Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. Completed NCT01939977 Phase 4
19 START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Completed NCT00132431 Phase 4
20 Vitamin D Repletion in Primary Hyperparathyroidism Completed NCT01306656 Phase 4
21 Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism Completed NCT00123461 Phase 4
22 Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Completed NCT00891813 Phase 4
23 Treatment Adhesion in Dialysis Patients Treated With Cinacalcet Completed NCT01573520 Phase 4
24 A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection Completed NCT00463021 Phase 4
25 Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level Completed NCT01101113 Phase 4
26 20070360 Incident Dialysis Completed NCT00803712 Phase 4
27 A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis Completed NCT00418600 Phase 4
28 Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients Completed NCT00958451 Phase 4
29 Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium Completed NCT00073710 Phase 4
30 The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid Completed NCT02056730 Phase 4
31 Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D Completed NCT00977080 Phase 4
32 A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis Completed NCT00454350 Phase 4
33 How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis Completed NCT00528788 Phase 4
34 A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients Completed NCT01506947 Phase 4
35 A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD) Completed NCT00431496 Phase 4
36 Paricalcitol Effect on Anemia in CKD Completed NCT01768351 Phase 4
37 Trial to Optimize Mineral Outcomes in Dialysis Patients Completed NCT01100723 Phase 4
38 Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis Completed NCT00053547 Phase 4
39 A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease Completed NCT00257920 Phase 4
40 A Research Study for Patients With End-Stage Renal Disease (ESRD) Completed NCT00110890 Phase 4
41 Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density Completed NCT01025128 Phase 4
42 CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients Completed NCT00211939 Phase 4
43 Vitamin D and Coronary Calcification Study Completed NCT00752102 Phase 4
44 Study of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease Completed NCT00395382 Phase 4
45 Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol Completed NCT01748396 Phase 4
46 Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy Completed NCT00319761 Phase 4
47 Uremic Pruritus, Cytokines and Polymethylmethacrylate Artificial Kidney Completed NCT00442819 Phase 4
48 Prospective Study of Profile of Hepatic Osteodystrophy in Patients With Non-Choleastatic Liver Cirrhosis and Impact of Bisphosphonate Supplementation Completed NCT02249741 Phase 4
49 Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder Completed NCT01633853 Phase 4
50 ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Completed NCT00379899 Phase 4

Search NIH Clinical Center for Hyperparathyroidism

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: hyperparathyroidism

Genetic Tests for Hyperparathyroidism

Genetic tests related to Hyperparathyroidism:

id Genetic test Affiliating Genes
1 Hyperparathyroidism 29

Anatomical Context for Hyperparathyroidism

MalaCards organs/tissues related to Hyperparathyroidism:

39
Bone, Kidney, Thyroid, Testes, Endothelial, Liver, Breast

Publications for Hyperparathyroidism

Articles related to Hyperparathyroidism:

(show top 50) (show all 1961)
id Title Authors Year
1
Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis. ( 28063122 )
2017
2
Bipolar Disorder With Mixed Features Associated With Primary Hyperparathyroidism. ( 28010754 )
2017
3
Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitaminA D in Austria and Switzerland - the observational TRANSIT Study. ( 28091752 )
2017
4
Hyperparathyroidism caused by distant pulmonary lesions and parathyromatosis after ethanol injection/parathyroidectomy for secondary hyperparathyroidism. ( 28078796 )
2017
5
Unilateral Clearance for Primary Hyperparathyroidism in Selected Patients with Multiple Endocrine Neoplasia Type 1: Reply. ( 27847968 )
2017
6
Ultrasound-based scores as predictors for nodular hyperplasia in patients with secondary hyperparathyroidism: a prospective validation study. ( 28054194 )
2017
7
Operative intervention for primary hyperparathyroidism offers greater bone recovery in patients with sporadic disease than in those with multiple endocrine neoplasia type 1-related hyperparathyroidism. ( 27842919 )
2017
8
Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism. ( 28073343 )
2017
9
A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. ( 28057872 )
2017
10
Erratum to: Musculoskeletal manifestations of primary hyperparathyroidism. ( 28091807 )
2017
11
ANALYSIS OF FACTORS AFFECTING OUTCOME OF ULTRASOUND-GUIDED RADIOFREQUENCY HEAT ABLATION FOR TREATMENT OF PRIMARY HYPERPARATHYROIDISM IN DOGS. ( 27885739 )
2017
12
Management of secondary hyperparathyroidism: how and why? ( 28044233 )
2017
13
Heterozygous inactivating CaSR mutations causing neonatal hyperparathyroidism: function, inheritance and phenotype. ( 27666534 )
2016
14
Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism. ( 27873072 )
2016
15
Clinical Expression of Calcium Sensing Receptor Polymorphism (A986S) in Normocalcemic and Asymptomatic Hyperparathyroidism. ( 26332755 )
2016
16
Fluorine-18 fluorocholine PET-CT localizes hyperparathyroidism in patients with inconclusive conventional imaging: a multicenter study from the Netherlands. ( 27612033 )
2016
17
Prospective Validation of Two 4D-CT-Based Scoring Systems for Prediction of Multigland Disease in Primary Hyperparathyroidism. ( 27659191 )
2016
18
A life-threatening duodenal ulcer hemorrhage due to previously unknown primary hyperparathyroidism. ( 27616071 )
2016
19
Cinacalcet versus Parathyroidectomy in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation. ( 27658167 )
2016
20
Hyperparathyroidism-jaw Tumor Syndrome: An Overlooked Cause of Severe Hypercalcemia. ( 27650236 )
2016
21
Focused Versus Bilateral Parathyroid Exploration for Primary Hyperparathyroidism: A Systematic Review and Meta-analysis. ( 27896505 )
2016
22
Primary Hyperparathyroidism Through an Ectopic Parathyroid Adenoma. ( 27172530 )
2016
23
Surgical treatment of primary hyperparathyroidism due to parathyroid tumor: A 15-year experience. ( 27602126 )
2016
24
Primary hyperparathyroidism. ( 27194390 )
2016
25
Surgical treatment for mediastinal parathyroid adenoma causing primary hyperparathyroidism. ( 27056365 )
2016
26
Literature review in the treatment of calciphylaxis: A case with uncontrolled and severe secondary hyperparathyroidism. ( 26958335 )
2016
27
In Response to the Article Entitled "Unilateral Clearance for Primary Hyperparathyroidism in Selected Patients with Multiple Endocrine Neoplasia Type 1". ( 27646283 )
2016
28
MAJOR MOLECULAR GENETIC DRIVERS IN SPORADIC PRIMARY HYPERPARATHYROIDISM. ( 28066056 )
2016
29
The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. ( 27532368 )
2016
30
Is focused parathyroidectomy appropriate for patients with primary hyperparathyroidism? ( 27617249 )
2016
31
Recurrence of Hyperparathyroid Hypercalcemia in a Patient With the HRPT-2 Mutation and a Previous Parathyroid Carcinoma in Hyperparathyroidism-Jaw Tumor Syndrome. ( 27679651 )
2016
32
Interest of video-assisted minimally invasive surgery in primary hyperparathyroidism. ( 27133292 )
2016
33
Ossification of the cervical ligamentum flavum and osseous brown tumor: late manifestations of primary hyperparathyroidism misdiagnosed in a case of parathyroid carcinoma. ( 27252748 )
2016
34
A case of hypercalcaemic crisis secondary to coexistence of primary hyperparathyroidism and Graves' disease. ( 27941175 )
2016
35
Comparative efficacy of parathyroidectomy and active surveillance in patients with mild primary hyperparathyroidism: a systematic review and meta-analysis. ( 27562567 )
2016
36
Neonatal severe hyperparathyroidism caused by homozygous mutation in CASR: A rare cause of life-threatening hypercalcemia. ( 26855056 )
2016
37
Persistent Primary Hyperparathyroidism, Severe Vitamin D Deficiency, and Multiple Pathological Fractures. ( 27525132 )
2016
38
Vitamin D status in primary hyperparathyroidism: effect of genetic background. ( 27154872 )
2016
39
Warfarin skin necrosis mimicking calciphylaxis in a patient with secondary hyperparathyroidism undergoing peritoneal dialysis. ( 27069859 )
2016
40
How Best to Approach Surgery for Primary Hyperparathyroidism-Can We All Agree? ( 27533602 )
2016
41
Ambulatory bilateral neck exploration for primary hyperparathyroidism: is it safe? ( 27659156 )
2016
42
Recurrent hyperparathyroidism due to proliferation of autotransplanted parathyroid tissue in a multiple endocrine neoplasia type 2A patient. ( 27617256 )
2016
43
Novel multiple endocrine neoplasia type 1 variations in patients with sporadic primary hyperparathyroidism. ( 27366707 )
2016
44
(18)F-FET-PET in Primary Hyperparathyroidism: A Pilot Study. ( 27548229 )
2016
45
Endocrine neoplasms in familial syndromes of hyperparathyroidism. ( 27207564 )
2016
46
Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia. ( 27933339 )
2016
47
Slipped Capital Femoral Epiphysis and Primary Hyperparathyroidism: A Case Report. ( 27920593 )
2016
48
A rare case report on recurrent acute pancreatitis secondary to primary hyperparathyroidism. ( 27728265 )
2016
49
Hyperparathyroidism jaw tumour syndrome: a pictoral review. ( 27651062 )
2016
50
Primary hyperparathyroidism: An unusual presentation. ( 27528246 )
2016

Variations for Hyperparathyroidism

Expression for Hyperparathyroidism

Search GEO for disease gene expression data for Hyperparathyroidism.

Pathways for Hyperparathyroidism

GO Terms for Hyperparathyroidism

Cellular components related to Hyperparathyroidism according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 BGLAP CALCA CHGA EPO FGF23 GAST
2 extracellular space GO:0005615 9.28 BGLAP CALCA CHGA EPO FGF23 GAST

Biological processes related to Hyperparathyroidism according to GeneCards Suite gene sharing:

(show all 29)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.95 BGLAP CDKN1B PTH RET TNFRSF11B
2 negative regulation of cell proliferation GO:0008285 9.93 CDC73 CDKN1B CYP27B1 MEN1 PTHLH VDR
3 response to lipopolysaccharide GO:0032496 9.9 ACP5 CYP27B1 EPO TNFRSF11B
4 cellular calcium ion homeostasis GO:0006874 9.78 CALCA CASR PTH VDR
5 negative regulation of epithelial cell proliferation GO:0050680 9.77 CDC73 CDKN1B MEN1
6 positive regulation of cAMP biosynthetic process GO:0030819 9.74 CALCA PTH PTHLH
7 adenylate cyclase-activating G-protein coupled receptor signaling pathway GO:0007189 9.73 CALCA PTH PTHLH
8 bone mineralization GO:0030282 9.71 BGLAP CYP27B1 PHEX
9 positive regulation of ossification GO:0045778 9.64 CALCA PTH
10 response to inorganic substance GO:0010035 9.64 BGLAP TNFRSF11B
11 positive regulation of keratinocyte differentiation GO:0045618 9.63 CYP27B1 VDR
12 skeletal system development GO:0001501 9.63 BGLAP PHEX PTH PTHLH TNFRSF11B VDR
13 response to magnesium ion GO:0032026 9.62 FGF23 TNFRSF11B
14 negative regulation of bone resorption GO:0045779 9.62 CALCA TNFRSF11B
15 response to estrogen GO:0043627 9.62 BGLAP CYP27B1 EPO TNFRSF11B
16 vitamin D metabolic process GO:0042359 9.61 CYP27B1 FGF23
17 cellular response to parathyroid hormone stimulus GO:0071374 9.61 FGF23 PHEX
18 decidualization GO:0046697 9.61 CYP27B1 MEN1 VDR
19 response to fibroblast growth factor GO:0071774 9.58 CASR PTH
20 negative regulation of calcium ion transport into cytosol GO:0010523 9.58 CALCA EPO
21 regulation of bone mineralization GO:0030500 9.58 BGLAP CYP27B1 FGF23
22 response to vitamin D GO:0033280 9.56 BGLAP CYP27B1 PHEX PTH
23 osteoblast development GO:0002076 9.54 BGLAP MEN1 PTHLH
24 cAMP metabolic process GO:0046058 9.52 PTH PTHLH
25 vitamin D catabolic process GO:0042369 9.51 CYP27B1 FGF23
26 response to sodium phosphate GO:1904383 9.49 FGF23 PHEX
27 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.13 CYP27B1 FGF23 VDR
28 cellular response to vitamin D GO:0071305 8.92 BGLAP CASR FGF23 PHEX
29 negative regulation of transcription, DNA-templated GO:0045892 10.03 CALCA CDKN1B MEN1 NR1I3 VDR

Molecular functions related to Hyperparathyroidism according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.02 CALCA EPO GAST PTH PTHLH
2 peptide hormone receptor binding GO:0051428 8.96 PTH PTHLH

Sources for Hyperparathyroidism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....